228 related articles for article (PubMed ID: 29359679)
1. Emerging Metabolomics Biomarkers of Polycystic Ovarian Syndrome; Targeting the Master Metabolic Disrupters for Diagnosis and Treatment.
Omabe M; Elom S; Omabe KN
Endocr Metab Immune Disord Drug Targets; 2018; 18(3):221-229. PubMed ID: 29359679
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic Insight into Polycystic Ovary Syndrome-An Overview.
Rajska A; Buszewska-Forajta M; Rachoń D; Markuszewski MJ
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32659951
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics in polycystic ovary syndrome.
Murri M; Insenser M; Escobar-Morreale HF
Clin Chim Acta; 2014 Feb; 429():181-8. PubMed ID: 24368231
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential metabolic biomarkers of polycystic ovary syndrome in follicular fluid by SWATH mass spectrometry.
Sun Z; Chang HM; Wang A; Song J; Zhang X; Guo J; Leung PCK; Lian F
Reprod Biol Endocrinol; 2019 Jun; 17(1):45. PubMed ID: 31186025
[TBL] [Abstract][Full Text] [Related]
5. Metabolic alterations associated with polycystic ovary syndrome: A UPLC Q-Exactive based metabolomic study.
Chen X; Lu T; Wang X; Sun X; Zhang J; Zhou K; Ji X; Sun R; Wang X; Chen M; Ling X
Clin Chim Acta; 2020 Mar; 502():280-286. PubMed ID: 31758934
[TBL] [Abstract][Full Text] [Related]
6. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome.
Chang AY; Lalia AZ; Jenkins GD; Dutta T; Carter RE; Singh RJ; Nair KS
Metabolism; 2017 Jun; 71():52-63. PubMed ID: 28521878
[TBL] [Abstract][Full Text] [Related]
7. UPLC/Q‑TOF‑MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome.
Fan X; Jiang J; Huang Z; Gong J; Wang Y; Xue W; Deng Y; Wang Y; Zheng T; Sun A; Luo G
Mol Med Rep; 2019 Jan; 19(1):280-292. PubMed ID: 30431132
[TBL] [Abstract][Full Text] [Related]
8. Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial.
Ni CM; Huang WL; Jiang YM; Xu J; Duan R; Zhu YL; Zhu XP; Fan XM; Luo GA; Wang YM; Li YY; He Q; Xu L
Trials; 2020 Feb; 21(1):169. PubMed ID: 32046752
[TBL] [Abstract][Full Text] [Related]
9. UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance.
Chen YX; Zhang XJ; Huang J; Zhou SJ; Liu F; Jiang LL; Chen M; Wan JB; Yang DZ
J Pharm Biomed Anal; 2016 Mar; 121():141-150. PubMed ID: 26808063
[TBL] [Abstract][Full Text] [Related]
10. Metabolomic Biomarkers in Polycystic Ovary Syndrome: A Review of the Evidence.
Alesi S; Ghelani D; Mousa A
Semin Reprod Med; 2021 Jul; 39(3-04):102-110. PubMed ID: 33946122
[TBL] [Abstract][Full Text] [Related]
11. Lipidomics biomarkers in women with polycystic ovary syndrome (PCOS) using ultra-high performance liquid chromatography-quadrupole time of flight electrospray in a positive ionization mode mass spectrometry.
Vonica CL; Ilie IR; Socaciu C; Moraru C; Georgescu B; Farcaş A; Roman G; Mureşan AA; Georgescu CE
Scand J Clin Lab Invest; 2019 Oct; 79(6):437-442. PubMed ID: 31462125
[TBL] [Abstract][Full Text] [Related]
12. Serum metabolomics of Indian women with polycystic ovary syndrome using
RoyChoudhury S; Mishra BP; Khan T; Chattopadhayay R; Lodh I; Datta Ray C; Bose G; Sarkar HS; Srivastava S; Joshi MV; Chakravarty B; Chaudhury K
Mol Biosyst; 2016 Oct; 12(11):3407-3416. PubMed ID: 27714060
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening.
Omabe M; Omabe KN; Clement FA; Omabe GM
Endocr Metab Immune Disord Drug Targets; 2016; 16(1):61-71. PubMed ID: 26832357
[TBL] [Abstract][Full Text] [Related]
14. Urinary volatile metabolomics as a viable alternative diagnostic tool for polycystic ovary syndrome: An exploratory hypothesis.
Sankarganesh D; Suriyakalaa U; Ramachandran R; Achiraman S; Arunachalam S; Angayarkanni J
Med Hypotheses; 2019 Mar; 124():121-124. PubMed ID: 30798906
[TBL] [Abstract][Full Text] [Related]
15. NMR Metabolomics Show Evidence for Mitochondrial Oxidative Stress in a Mouse Model of Polycystic Ovary Syndrome.
Selen ES; Bolandnazar Z; Tonelli M; Bütz DE; Haviland JA; Porter WP; Assadi-Porter FM
J Proteome Res; 2015 Aug; 14(8):3284-91. PubMed ID: 26076986
[TBL] [Abstract][Full Text] [Related]
16. Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS.
Wang W; Wang S; Tan S; Wen M; Qian Y; Zeng X; Guo Y; Yu C
Clin Chim Acta; 2015 Aug; 448():39-47. PubMed ID: 26093338
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel serum metabolic biomarkers in patients with polycystic ovarian syndrome and premature ovarian failure.
Chen J; Zhou Q; Zhang Y; Tan W; Gao H; Zhou L; Xiao S; Gao J; Li J; Zhu Z
Bioengineered; 2021 Dec; 12(1):8778-8792. PubMed ID: 34696698
[TBL] [Abstract][Full Text] [Related]
18. Subclinical hypothyroidism does not influence the metabolic and hormonal profile of women with PCOS.
Trakakis E; Pergialiotis V; Hatziagelaki E; Panagopoulos P; Salloum I; Papantoniou N
Horm Mol Biol Clin Investig; 2017 Jun; 31(3):. PubMed ID: 28672734
[TBL] [Abstract][Full Text] [Related]
19. Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry.
Jia C; Xu H; Xu Y; Xu Y; Shi Q
Mol Reprod Dev; 2019 Mar; 86(3):292-297. PubMed ID: 30624822
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 25-hydroxyvitamin D and metabolic parameters between women with and without polycystic ovarian syndrome.
Ng BK; Lee CL; Lim PS; Othman H; Ismail NAM
Horm Mol Biol Clin Investig; 2017 Jun; 31(3):. PubMed ID: 28586302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
